Related Experiment Video
Updated: Aug 12, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Population-based impact of pneumococcal conjugate vaccine in young children
Katherine A Poehling1, Bonnie J Lafleur, Peter G Szilagyi
1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2637, USA.
Insights
The pneumococcal conjugate vaccine (PCV) significantly reduced pneumonia and otitis media in young children. This vaccine
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Public health epidemiology
Background:
- Pneumococcal conjugate vaccines (PCV) target Streptococcus pneumoniae, a leading cause of childhood illness.
- Assessing the real-world population impact of PCV beyond invasive pneumococcal disease is crucial for public health policy.
Purpose of the Study:
- To evaluate the population-level effect of PCV on pneumococcal-related diseases, specifically pneumonia and otitis media, in young children.
- To quantify the reduction in medical visits for these conditions following PCV introduction.
Main Methods:
- Utilized administrative healthcare data from Tennessee Medicaid and New York commercial insurance plans.
- Compared annual disease rates for pneumonia and otitis media in children <2 years (PCV-eligible) versus 3-5 years (not routinely vaccinated) before and after PCV licensure (2000).
- Calculated the difference between observed and expected disease rates in PCV-eligible children to estimate vaccine impact.
Main Results:
- PCV introduction was associated with a significant decline in pneumonia-related medical visits: 20 fewer per 1000 children in Tennessee and 33 fewer in New York.
- Otitis media visits decreased substantially: 118 fewer per 1000 children in Tennessee and 430 fewer in New York.
- The observed reductions in pneumonia and otitis media were considerably larger than the impact on invasive pneumococcal disease.
Conclusions:
- Routine childhood immunization with PCV led to a substantial reduction in pneumonia and otitis media, exceeding its impact on invasive pneumococcal disease.
- The population-level impact of PCV on common pneumococcal-related illnesses is significantly greater than previously estimated based on invasive disease alone.
- These findings underscore the broad public health benefits of PCV in reducing childhood respiratory infections.
Objective:
To determine the population impact of pneumococcal conjugate vaccine (PCV) on pneumococcal-related diseases, including pneumonia and otitis media.
Methods:
Using administrative data from Tennessee Medicaid and 3 commercial insurance plans in upstate New York, we measured annual rates of medical visits for pneumococcal-related diseases (pneumococcal and nonspecific pneumonia and invasive disease; otitis media) and pneumococcal-unrelated diseases (other acute respiratory illnesses). Disease rates before (1995-2000 in Tennessee; 1998-2000 in New York) and after (2000-2002) PCV licensure were calculated for children aged <2 years (eligible for PCV) and those 3 to 5 years (not routinely given PCV). Because annual variations should affect both age groups similarly and vaccine-related outcomes should preferentially decline in younger children, ratios (<2:3-5 years) of disease rates before and after PCV licensure were compared. Expected disease rates were calculated for children aged <2 years in each postvaccine year. The difference between observed and expected disease rates was the estimated vaccine effect.
Results:
In 2001-2002, there were 67 380 and 9485 child-years of observation for Tennessee and New York children aged <2 years, respectively. We observed fewer visits for pneumonia and invasive disease per 1000 children than expected in both regions: 20 fewer emergency department or outpatient visits in Tennessee and 33 fewer outpatient visits in New York. Otitis media visits declined by 118 and 430 per 1000 children in Tennessee and New York, respectively.
Conclusions:
Adding PCV to the childhood immunization schedule was associated with a 10-fold greater reduction in pneumonia and a 100-fold greater reduction in otitis media than the previously reported reduction in culture-confirmed invasive pneumococcal diseases of 1.3 episodes per 1000 children aged <2 years. Although additional studies are needed to confirm the impact of routine immunization with PCV on pneumococcal-related disease, these results suggest that its impact is substantially greater than the effects on invasive disease alone.
Related Concept Videos
Vaccinations
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children
Streptococcal Pharyngitis
Smallpox
Poliomyelitis

